Alpha Tau Medical Ltd. (DRTS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−25.2x

Market Cap

$1.32B

MomentumView details →

1D Return

+2.80%

YTD Return

+204.55%

RSI (14)

63.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−25.2x

Market Cap

$1.32B

RSI (14)

63.0

MomentumView details →

1D Return

+2.80%

YTD Return

+204.55%

SummaryUpdated Jun 1, 2026

Alpha Tau Medical Ltd. (NASDAQ:DRTS) is a clinical-stage oncology therapeutics company founded in 2015 and headquartered in Jerusalem, Israel. The company went public in March 2021 and focuses on developing innovative radiation therapy technology for treating solid tumors. Alpha Tau's core innovation centers around a proprietary technology called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), which represents a novel approach to cancer treatment using radioactive alpha particles delivered directly to tumor sites.

Ask drillr about Alpha Tau Medical Ltd. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−210.13%

ROA (TTM)

−68.96%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−17.78%

EBITDA YoY

−53.79%

EarningsView details →

EPS (Actual)

−$0.50

EPS Surprise

−254.91%

Beats (12Q)

6/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

−96.82%

Rev Surprise

−30.80%

Capital & dividendView details →

Debt/Equity

0.34x

Current Ratio

11.09x

Quick Ratio

11.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−92.57M

Op. CF (TTM)

−26.68M

Next earningsNov 19, 2026 →

Latest newsMore news →

Alpha Tau Medical completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for unresectable pancreatic cancer, expanding enrollment from 12 to 48 patients.4d ago

Alpha Tau Medical reported positive clinical data for Alpha DaRT in combination with pembrolizumab in head and neck cancer at the AHNS conference on July 21, 2026.45d ago

Similar companies

ORIC Pharmaceuticals, Inc.ORIC MeiraGTx Holdings plcMGTX MannKind CorporationMNKD MoonLake ImmunotherapeuticsMLTX Omeros CorporationOMER Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK Find similar companies →

Latest newsMore news →

Alpha Tau Medical completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for unresectable pancreatic cancer, expanding enrollment from 12 to 48 patients.4d ago Alpha Tau Medical reported positive clinical data for Alpha DaRT in combination with pembrolizumab in head and neck cancer at the AHNS conference on July 21, 2026.45d ago Alpha Tau successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center.51d ago